Giant cell cancer of the lung: Diagnosis and treatment monitoring with PET/CT

Mary E. Miller, Alison M. Coates, Maqbool A. Halepota, Eric R. Kovalsky, Susan Passalaqua, Michael B. Gotway, Ronald L. Korn

Research output: Contribution to journalShort surveypeer-review


Bronchogenic carcinoma is the most common primary tumor affecting lung. Four main histopathological subtypes of bronchogenic carcinoma are recognized, and several variants of these histopathological subtypes are also known. Among the 4 main histopathological subtypes of bronchogenic carcinoma, large cell carcinoma is the least commonly encountered. Rarer still is a subtype of large cell carcinoma known as giant cell carcinoma. We report the detection and characterization of pulmonary giant cell carcinoma using 18F-fluoro-2- deoxyglucose positron emission tomography/computed tomography (FDG-PET-CT). FDG-PET-CT showed intense hypermetabolic activity within the primary lesion, which subsequently decreased, and then resolved following antineoplastic therapy. FDG-PET-CT also allowed detection of sites of recurrence of the tumor following cessation of therapy. This report highlights the usefulness of FDG-PET-CT for the detection of an unusual thoracic neoplasm as well as the ability of FDG-PET-CT for assessing response to therapy.

Original languageEnglish (US)
Pages (from-to)106-108
Number of pages3
JournalClinical Pulmonary Medicine
Issue number2
StatePublished - Mar 2010


  • Computed tomography
  • Giant cell carcinoma of lung
  • Hypermetabolic
  • Large cell carcinoma
  • Non-small-cell carcinoma
  • Positron emission tomography
  • Pulmonary neoplasia
  • Response to therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Giant cell cancer of the lung: Diagnosis and treatment monitoring with PET/CT'. Together they form a unique fingerprint.

Cite this